ReviewEuropean respiratory review : an official journal of the European Respiratory Society2021
Asthma and COVID-19: an update.
Review in European respiratory review : an official journal of the European Respiratory Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Impact of Coronavirus Disease (COVID)-19 on the Indigenous Population of Brazil: A Systematic Review.Journal of racial and ethnic health disparities · 2026Pooled it
- Asthma and COPD as co-morbidities in patients hospitalised with Covid-19 disease: a global systematic review and meta-analysis.BMC pulmonary medicine · 2023Pooled it
- Organokines in COVID-19: A Systematic Review.Cells · 2023Pooled it
- Inhaled Ciclesonide for Community-Based COVID-19: A Placebo-Controlled Randomised Trial.Respirology (Carlton, Vic.) · 2026Trial
- Changes in patient conceptualization of asthma and asthma self-management at key timepoints across the COVID-19 pandemic: A qualitative study.British journal of health psychology · 2026Article
- Risk assessment of cardiac arrhythmias in the early post-COVID-19 period in non-hospitalized patients-long-term data from the PoLoCOV-CVD study.Scientific reports · 2026Observational
- New Simplified White Blood Cells Score Improves Mortality Prediction in Severe COVID-19 Patients.Journal of clinical medicine · 2026Article
- Exacerbations and Management of Asthma in Viral Lower Respiratory Tract Infections: The Significance of Immunoglobulin E.Immunity, inflammation and disease · 2026Review
- Uncontrolled Asthma and Severe COVID-19: A Prospective Bidirectional Risk Analysis.Journal of asthma and allergy · 2026Article
- The impact of COVID-19 on the incidence of allergic diseases in the pediatric population: A retrospective cohort study from TriNetX United States collaborative network.Asia Pacific allergy · 2025Article
- Impact of COVID-19 pandemic on childhood asthma and wheezing disorders.World journal of pediatrics : WJP · 2025Article
- Clinical outcomes of persistent cough following coronavirus disease 2019 infection: A 1-year retrospective cohort study.Asia Pacific allergy · 2025Article
- Observational Study: Lung Function and Symptom Control in Youth With Asthma up to 34 Months After COVID-19.Pediatric pulmonology · 2025Observational
- Unraveling the mechanisms of virus-induced asthma exacerbation: epithelial injury, immune dysregulation, and novel interventions.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Impact of Loneliness and Social Support on Acute Health Service Use and Symptom Exacerbation Among Adults with Asthma and COPD.Journal of clinical psychology in medical settings · 2025Article
- Preschool Asthma Children: Navigating COVID-19's Impact on Treatment Adherence.Turkish archives of pediatrics · 2025Article
- Three-Year Follow-Up of COVID-19 Cases in District of Constance, Germany. A Prospective, Controlled Cohort Study (FSC19-KN).Journal of clinical medicine · 2025Article
- Non-Pharmaceutical Interventions May Attenuate Acute Exacerbations of Asthma: Experience During the COVID-19 Pandemic in Taiwan.Journal of asthma and allergy · 2025Article
- Evaluation of the case fatality rate in 2 031 309 hospitalised Brazilian patients due to COVID-19: An observational study of the first 3 years of the pandemic in Brazil.BMJ public health · 2025Article
- Trends in mortality due to asthma in young adults between 1999 and 2020: an analysis of CDC WONDER database.Proceedings (Baylor University. Medical Center) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the world faces the coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, concerns have been raised that asthma patients could be at increased risk of SARS-CoV-2 infection and disease severity. However, it appears that asthma is not an independent risk factor for both. Furthermore, asthma is not over-represented in hospitalised patients with severe pneumonia due to SARS-CoV-2 infection and there was no increased risk of asthma exacerbations triggered by SARS-CoV-2. There is accumulating evidence that asthma phenotypes and comorbidities are important factors in evaluating the risk for SARS-CoV-2 infection and disease severity, as findings suggest that Th2-high inflammation may reduce the risk of SARS-Cov-2 infection and disease severity in contrast to increased risk in patients with Th2-low asthma. The use of inhaled corticosteroids (ICS) is safe in asthma patients with SARS-CoV-2 infection. Furthermore, it has been proposed that ICS may confer some degree of protection against SARS-CoV-2 infection and the development of severe disease by reducing the expression of angiotensin converting enzyme-2 and transmembrane protease serine in the lung. In contrast, chronic or recurrent use of systemic corticosteroids before SARS-CoV-2 infection is a major risk factor of poor outcomes and worst survival in asthma patients. Conversely, biological therapy for severe allergic and eosinophilic asthma does not increase the risk of being infected with SARS-CoV-2 or having worse COVID-19 severity. In the present review we will summarise the current literature regarding asthma and COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.